One antisense drug, Isis Pharmaceuticals' (Carlsbad ... application of further chemical modifications such as peptide nucleic acids (PNAs), locked nucleic acid (LNA), and phosporodiamidate ...

Splice-switching antisense oligonucleotide controlling tumor suppressor REST is a novel therapeutic medicine for neuroendocrine cancer, Molecular Therapy - Nucleic Acids (2024). DOI: 10.1016/j.omtn.

Expands DNAbilize® Technology Beyond Oncology into ObesityConference Call to be Held Today at 8:30 A.M. ETHOUSTON, Nov. 15, 2024 (GLOBE ...

Bio-Path Holdings ( (BPTH) ) has released its Q3 earnings. Here is a breakdown of the information Bio-Path Holdings presented to its investors.